An expansion to BIA Separations' Cornerstone set of processing services for viral vector development adds the use of kryptonase and CIMmultus chromatography device.
Trialbee and TriNetX are teaming up to accelerate research and develop new services with the goal of improving patient access to clinical trials as a care option.
Trinity’s acquisition of Bell Canyon aims to create an integrated data management offering that will enable all members of a development project to gain access to ‘a single version of truth.’
Aetion and McKesson today announced a strategic collaboration to advance the use of real world evidence in cancer research – offering joint solutions to support the FDA’s demonstration project and commercial customers.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.
The goal of the partnership between Life Image and Graticule is to improve clinical trial results and accelerate drug development, while reducing costs, say company executives.
US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.
A consortium between CPI and the University of Strathclyde aims to create a direct compression platform for continuous manufacturing of oral solid dosage drugs.
With global health care ‘at a tipping point,’ NSF International expands its services across the product lifecycle with the acquisition of a US-headquartered CRO, says VP.
The FDA has published the second in a series of guidance documents that aim to accelerate research and the use of patient input to inform clinical development programs, says Iqvia head.
Broad adoption of blockchain technology requires manufacturers to look at their investments in the supply chain, just as they look at R&D, AmerisourceBergen executive says.
With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
The clinical trials software company has raised $7.1m to connect its network of more than 5,000 clinical trial sites with sponsors and CROs via the ‘Florence eHub.’
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
TriNetX is a new technology partner working on the FDA’s Sentinel System, led by HPHCI, which has signed a contract worth up to $220m to develop a new Sentinel Innovation Center.
A fellowship program run by Worldwide Clinical Trials aims to equip scientists with the skills to meet industry demands for ‘informed, differentiated’ services.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
Beacon of Hope CRO is working with sponsors and other service providers to design Right to Try treatment programs, which the company’s founder says have ‘unmatched’ flexibility, an ability to treat screen fails and create ‘interim clinical milestones,’...
Three organizations have merged to form Apex Innovative Sciences, an independent clinical trial site operator focused on Phase I-IV studies for central nervous system indications and other therapeutic areas, including neurology, psychiatry, addiction,...
Through a recently announced partnership with TrialSpark, 23andMe has entered the clinical trials market – an area in which the direct-to-consumer genetic testing company feels it has the potential to grow.
Parexel increases its real world data network by more than 330m patients across 60 health care and consumer sources though a partnership with HealthVerity – which earlier this year raised $25m to advance its technology.
Datacubed Health today launches the Linkt Location app, which tracks participant interactions with health care facilities, providing reminders and other communications to garner insight into health events that are often unreported.
A partnership between Sciex and Protein Metrics aims to make their services compatible with other software services available, enabling drug developers to work in an ‘open ecosystem.’
The recently-launched Research on Research Institute aims to deliver “transformative and translational research on research systems, cultures, and decision-making,” the need for which “has never been more vital,” says director.
After an investigation last year, the FDA cites problems across multiple sites within the Lupin manufacturing network, raising questions about ‘management oversight and control’.
US FDA expands the approval of Gilead’s Descovy to make it available for the PrEP indication, coming ahead of the entrance of generic rivals to the company’s Truvada product.
England’s High Court throws out the claim that Sandoz’s inhaler product passed off the appearance of GSK’s rival through its use of the color purple in packaging.
Iqvia’s Orchestrated Patient Engagement solution, powered by Belong.Life, delivers ‘hyper-personalized’ content to engage and support patients, providing insights that will benefit patients, life sciences companies, and the health care system, says CEO.
CAS collates the world’s largest collection of formulations – a ‘one-stop-shop’ that will help formulators innovate faster and solve problems, ultimately reducing drug development timelines, says project lead.
Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
LGC announces the addition of Quanterix’s HD-X platform to its offering, enabling automated development and performing of immunoassays for ‘unprecedented insights’ into disease biology as well as drug efficacy and safety.
Partnering with airlines is essential, says CSafe executive, as the company signs an agreement to use LOT Cargo’s to airplanes to transporttemperature-sensitive biologics.
LMC Manna is expanding its ability to provide clinical research as a care option to patients by integrating research within its clinics and physician practices – changing the dynamic of how research exists in Canada, says company executive.
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
Johnson & Johnson reaches $20m settlement with two US counties on lawsuits regarding the opioid crisis, exits the upcoming federal trial involving several drug manufacturers.
With nitrosamines back in the headlines due to the recent discovery of contaminants in ranitidine, the EMA releases the five potential causes of the impurities plaguing the industry.
